Information on share buy-back programme

MFN Publicerad: 28 Jul 2023 19:41

On 30 June, 2023, Gubra A/S (“Gubra” or the “Company”) announced that a share buy-back programme of approximately DKK 2.5 million and up to a maximum of 27,231 shares has been initiated with the purpose of meeting the Company's obligations arising from its share-based incentive programmes for employees of the Company.

Today, Gubra announces that 1,539 shares have been repurchased of the share buy-back programme. The details for each transaction made under the share buy-back programme is attached to this announcement. The repurchase of shares is expected to be resumed after the publication of the first half-year report 2023 (will be published on 25 August 2023).

With the transactions carried out under the programme, Gubra owns a total of 33,579 own shares, corresponding to 0.2% of the share capital of the Company. The total amount of shares in the company is 16,349,703 including treasury shares.

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Börskollen

För dig med koll på börsen

Pressmeddelande

Information on share buy-back programme

Bifogade filer

Nyheter om Gubra

Läses av andra just nu

Om aktien Gubra

Senaste nytt